RU2483080C2 - Антитела и иммуноконъюгаты и их применение - Google Patents
Антитела и иммуноконъюгаты и их применение Download PDFInfo
- Publication number
- RU2483080C2 RU2483080C2 RU2009119976/10A RU2009119976A RU2483080C2 RU 2483080 C2 RU2483080 C2 RU 2483080C2 RU 2009119976/10 A RU2009119976/10 A RU 2009119976/10A RU 2009119976 A RU2009119976 A RU 2009119976A RU 2483080 C2 RU2483080 C2 RU 2483080C2
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- immunoconjugate
- amino acid
- seq
- acid sequence
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title claims abstract 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 23
- 238000000034 method Methods 0.000 claims abstract 9
- 239000003814 drug Substances 0.000 claims abstract 8
- 238000001514 detection method Methods 0.000 claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract 3
- 201000011510 cancer Diseases 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 230000002062 proliferating effect Effects 0.000 claims 9
- 229940127089 cytotoxic agent Drugs 0.000 claims 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims 5
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- -1 6-maleimidocaproyl Chemical group 0.000 claims 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 3
- 108010044540 auristatin Proteins 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 125000004452 carbocyclyl group Chemical group 0.000 claims 3
- 229960002173 citrulline Drugs 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 201000011281 bladder sarcoma Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 201000002660 colon sarcoma Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000003866 lung sarcoma Diseases 0.000 claims 2
- 230000001293 nucleolytic effect Effects 0.000 claims 2
- 208000011932 ovarian sarcoma Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 201000008079 ovary sarcoma Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 201000002025 prostate sarcoma Diseases 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
- 108010011559 alanylphenylalanine Proteins 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical group C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract 1
- 0 CC(C(*)C(CCC1)N1C(CC(*)C(*)N(*)C(C(*)(*)N*(C(*)N(C)*)=O)=O)=O)C(N(*)C(C*)C(**)=O)=O Chemical compound CC(C(*)C(CCC1)N1C(CC(*)C(*)N(*)C(C(*)(*)N*(C(*)N(C)*)=O)=O)=O)C(N(*)C(C*)C(**)=O)=O 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
Abstract
Изобретение относится к области иммунологии. Предложено гуманизированное антитело, специфичное к STEAP-1, которое содержит тяжелую и легкую цепи с охарактеризованными аминокислотными последовательностями 6 CDR и каркасной областью FR1 тяжелой цепи. Описан способ детектирования STEAP-1, фармацевтическая композиция и иммуноконъюгат, а также цистеин-встроенное антитело на основе указанного антитела. Раскрыты: способ лечения рака, связанного с увеличенной экспрессией STEAP-1, а также фармацевтическая композиция и варианты иммуноконъюгата с использованием цистеин-встроенного антитела. Использование изобретения обеспечивает новые антитела к STEAP-1, что может найти применение в медицине. 12 н. и 44 з.п. ф-лы, 45 ил., 2 табл., 9 пр.
Description
Claims (56)
1. Гуманизированное моноклональное антитело, которое связывается с STEAP-1, содержащее тяжелую цепь (НС), содержащую:
(1) HVR-H1, содержащий аминокислотную последовательность SEQ ID NO:14;
(2) HVR-H2, содержащий аминокислотную последовательность SEQ ID NO:15;
(3) HVR-H3, содержащий аминокислотную последовательность SEQ ID NO:16; и
(4) HC-FR1, содержащий аминокислотную последовательность SEQ ID NO:25; и
легкую цепь (LC), содержащую:
(1) HVR-L1, содержащий аминокислотную последовательность SEQ ID NO:11;
(2) HVR-L2, содержащий аминокислотную последовательность SEQ ID NO:12; и
(3) HVR-L3, содержащий аминокислотную последовательность SEQ ID NO:13.
(1) HVR-H1, содержащий аминокислотную последовательность SEQ ID NO:14;
(2) HVR-H2, содержащий аминокислотную последовательность SEQ ID NO:15;
(3) HVR-H3, содержащий аминокислотную последовательность SEQ ID NO:16; и
(4) HC-FR1, содержащий аминокислотную последовательность SEQ ID NO:25; и
легкую цепь (LC), содержащую:
(1) HVR-L1, содержащий аминокислотную последовательность SEQ ID NO:11;
(2) HVR-L2, содержащий аминокислотную последовательность SEQ ID NO:12; и
(3) HVR-L3, содержащий аминокислотную последовательность SEQ ID NO:13.
2. Антитело по п.1, дополнительно содержащее по меньшей мере один, два или три каркасных района (FR), выбранных из
(1) HC-FR2, содержащего аминокислотную последовательность SEQ ID NO:22, 75 или 76;
(2) HC-FR3, содержащего аминокислотную последовательность SEQ ID NO:23, 78 или 79; и
(3) HC-FR4, содержащего аминокислотную последовательность SEQ ID NO:24.
(1) HC-FR2, содержащего аминокислотную последовательность SEQ ID NO:22, 75 или 76;
(2) HC-FR3, содержащего аминокислотную последовательность SEQ ID NO:23, 78 или 79; и
(3) HC-FR4, содержащего аминокислотную последовательность SEQ ID NO:24.
3. Антитело по п.1, в котором указанная LC содержит SEQ ID NO:6.
4. Антитело по п.1, где указанная НС содержит SEQ ID NO:10.
5. Антитело по п.3, где указанная НС содержит SEQ ID NO:10.
6. Антитело по п.1, где указанное антитело является фрагментом антитела, выбранным из фрагментов Fab, Fab'-SH, Fv, scFv или (Fab')2.
7. Способ детектирования присутствия STEAP-1 в биологической пробе, предусматривающий приведение биологической пробы в контакт с антителом по п.1 в условиях, допускающих связывание указанного антитела с STEAP-1, и детектирование того, образуется ли комплекс между антителом и STEAP-1.
8. Способ по п.7, где биологическая проба получена из организма пациента, предположительно имеющего клеточно-пролиферативное нарушение предстательной железы, легкого, ободочной кишки, мочевого пузыря, яичника или саркомы Юинга.
9. Иммуноконъюгат для применения в лечении и детектировании клеточно-пролиферативных нарушений, ассоциированных с увеличенной экспрессией STEAP-1, содержащий антитело по п.1, ковалентно связанное с цитотоксическим агентом.
10. Иммуноконъюгат по п.9, где цитотоксический агент выбран из токсина, химиотерапевтического агента, лекарственного средства, антибиотика, радиоактивного изотопа и нуклеолитического фермента.
11. Иммуноконъюгат по п.10, где иммуноконъюгат имеет формулу Ab-(L-D)p, и где:
(a) Ab означает антитело по п.1;
(b) L означает линкер;
(c) D означает лекарственное средство; и
(d) p изменяется в интервале приблизительно от 1 до 20.
(a) Ab означает антитело по п.1;
(b) L означает линкер;
(c) D означает лекарственное средство; и
(d) p изменяется в интервале приблизительно от 1 до 20.
12. Иммуноконъюгат по п.11, где L выбран из 6-малеимидокапроила (МС), малеимидопропаноила (МР), валин-цитруллина (val-cit), аланин-фенилаланина (ala-phe), п-аминобензилоксикарбонила (РАВ), N-сукцинимидил-4-(2-пиридилтио)пентаноата (SPP), N-сукцинимидил-4-(N-малеимидометил)циклогексан-1-карбоксилата (SMCC), N-сукцинимидил-(4-иодацетил)аминобензоата (SIAB) и 6-малеимидокапроил-валин-цитруллин-п-аминобензилоксикарбонила (MC-vc-PAB).
13. Иммуноконъюгат по п.11, где D выбран из ауристатина и доластатина.
14. Иммуноконъюгат по п.13, где D означает группу лекарственного средства формулы DE или DF
и где каждый из R2 и R6 означает метил, каждый из R3 и R4 означает изопропил, R5 означает Н, R7 означает втор-бутил, каждый R8 независимо выбран из СН3, O-СН3, ОН и Н; R9 означает Н; R10 означает арил; Z означает -О- или -NH-; R11 означает Н, C1-C8-алкил или - (СН2)2-O-(СН2)2-O-(СН2)2-O-СН3; и R18 означает -С(R8)2-С(R8)2-арил; и
p изменяется в интервале приблизительно от 1 до 8.
и где каждый из R2 и R6 означает метил, каждый из R3 и R4 означает изопропил, R5 означает Н, R7 означает втор-бутил, каждый R8 независимо выбран из СН3, O-СН3, ОН и Н; R9 означает Н; R10 означает арил; Z означает -О- или -NH-; R11 означает Н, C1-C8-алкил или - (СН2)2-O-(СН2)2-O-(СН2)2-O-СН3; и R18 означает -С(R8)2-С(R8)2-арил; и
p изменяется в интервале приблизительно от 1 до 8.
15. Иммуноконъюгат по п.11, имеющий активность, связанную с уничтожением клеток in vitro или in vivo.
16. Иммуноконъюгат по п.11, имеющий формулу Ab-(L-MMAE)p, где L означает линкер, а p изменяется в интервале от 2 до 5.
17. Иммуноконъюгат по п.16, где L содержит val-cit.
18. Иммуноконъюгат по п.16, где L содержит МС.
19. Иммуноконъюгат по п.16, где L содержит РАВ.
20. Иммуноконъюгат по п.16, где L содержит MC-vc-PAB.
21. Иммуноконъюгат по п.11, где D означает майтансиноид.
22. Иммуноконъюгат по п.21, где D выбран из DM1, DM3 и DM4.
23. Иммуноконъюгат по п.21, где указанный линкер присоединен к антителу через тиоловую группу на антителе.
24. Иммуноконъюгат по п.21, где указанный линкер, L, выбран из N-сукцинимидил-4-(2-пиридилтио)пентаноата (SPP), N-сукцинимидил-4-(N-малеимидометил)циклогексан-1-карбоксилата (SMCC) и N-сукцинимидил-(4-иодацетил)аминобензоата (SIAB).
25. Иммуноконъюгат по п.24, где D является DM4.
26. Иммуноконъюгат по п.25, где L содержит SPP.
27. Иммуноконъюгат по п.25, где L содержит SMCC.
28. Иммуноконъюгат по п.25, где p составляет от 2 до 6.
29. Фармацевтическая композиция для лечения и детектирования клеточно-пролиферативных нарушений, ассоциированных с увеличенной экспрессией STEAP-1, содержащая эффективное количество иммуноконъюгата по любому из пп.11 и 16-20 и фармацевтически приемлемый носитель.
30. Способ лечения клеточно-пролиферативного нарушения, ассоциированного с увеличенной экспрессией STEAP-1, предусматривающий введение индивидууму эффективного количества фармацевтической композиции по п.29.
31. Способ по п.30, где клеточно-пролиферативное нарушение выбрано из клеточно-пролиферативного нарушения предстательной железы, легкого, ободочной кишки, мочевого пузыря, яичника и саркомы Юинга.
32. Цистеин-встроенное антитело для применения в лечении и детектировании клеточно-пролиферативных нарушений, ассоциированных с увеличенной экспрессией STEAP-1, представляющее собой антитело по п.1, содержащее тяжелую цепь и легкую цепь, где один или более аминокислотных остатков в константной области указанной тяжелой цепи и/или легкой цепи заменены одним или несколькими аминокислотными остатками свободного цистеина, имеющими величину реакционной способности тиолов в интервале от 0,6 до 1,0.
33. Антитело по п.32, где один или более аминокислотных остатков свободного цистеина расположены в легкой цепи.
34. Антитело по п.32, где один или более аминокислотных остатков свободного цистеина расположены в тяжелой цепи.
35. Иммуноконъюгат для применения в лечении и детектировании клеточно-пролиферативных нарушений, ассоциированных с увеличенной экспрессией STEAP-1, содержащий антитело по п.32, ковалентно связанное с цитотоксическим агентом.
36. Иммуноконъюгат по п.35, где цитотоксический агент выбран из токсина, химиотерапевтического агента, лекарственного средства, антибиотика, радиоактивного изотопа и нуклеолитического фермента.
37. Антитело по п.32, ковалентно присоединенное к захватывающей метке, детектируемой метке или твердому носителю.
38. Иммуноконъюгат для применения в лечении и детектировании клеточно-пролиферативных нарушений, ассоциированных с увеличенной экспрессией STEAP-1, содержащий антитело по п.32, где указанное антитело ковалентно присоединено к лекарственному средству ауристатину или майтансиноиду.
39. Иммуноконъюгат для применения в лечении и детектировании клеточно-пролиферативных нарушений, ассоциированных с увеличенной экспрессией STEAP-1, содержащий антитело по п.32 (Ab) и лекарственное средство ауристатин или майтансиноид (D), причем антитело присоединено через один или более аминокислотных остатков свободного цистеина линкерной частью (L) к D; при этом соединение имеет формулу I:
где p изменяется в интервале от 1 до 4.
где p изменяется в интервале от 1 до 4.
40. Иммуноконъюгат по п.39, где p составляет приблизительно 2.
41. Иммуноконъюгат по п.39, где L имеет формулу
-Aa-Ww-Yy-,
в которой -А- означает удлиняющее звено, ковалентно связанное с цистеиновым тиолом цистеин-встроенного антитела (Ab);
а равно 0 или 1;
каждый -W- независимо означает аминокислотное звено;
w означает целое число, находящееся в интервале от 0 до 12;
-Y- означает спейсерное звено, ковалентно присоединенное к лекарственной части; и
y равно 0, 1 или 2.
-Aa-Ww-Yy-,
в которой -А- означает удлиняющее звено, ковалентно связанное с цистеиновым тиолом цистеин-встроенного антитела (Ab);
а равно 0 или 1;
каждый -W- независимо означает аминокислотное звено;
w означает целое число, находящееся в интервале от 0 до 12;
-Y- означает спейсерное звено, ковалентно присоединенное к лекарственной части; и
y равно 0, 1 или 2.
42. Иммуноконъюгат по п.41, имеющий формулу:
где РАВ означает пара-аминобензилкарбамоил, и R17 означает двухвалентный радикал, выбранный из (СН2)r, С3-C8 карбоциклила, O-(СН2)r, арилена, (CH2)r-арилена, -арилен-(СН2)r-, (СН2)r-(С3-С8 карбоциклила), (С3-C8 карбоциклил)-(СН3)r, С3-C8 гетероциклила, (СН2)r-(С3-C8 гетероциклила), -(С3-C8 гетероциклил)-(СН2)r, (CH2)rC(O)NRb(CH2)r-, -(СН2СН2О)r-, -(CH2CH2O)rCH2-, (CH2)rC(O)NRb(CH2CH2O)r-, -(CH2)rC(O)NRb(CH2CH2O)rCH2-, (CH2CH2O)rC(O)NRb(CH2CH2O)r-, -(CH2CH2O)rC(O)NRb(CH2CH2O)rCH2- и -(CH2CH2O)rC(O)NRb(CH2)r-; где Rb означает Н, C1-С6 алкил, фенил или бензил; и r независимо означает целое число, находящееся в интервале от 1 до 10.
где РАВ означает пара-аминобензилкарбамоил, и R17 означает двухвалентный радикал, выбранный из (СН2)r, С3-C8 карбоциклила, O-(СН2)r, арилена, (CH2)r-арилена, -арилен-(СН2)r-, (СН2)r-(С3-С8 карбоциклила), (С3-C8 карбоциклил)-(СН3)r, С3-C8 гетероциклила, (СН2)r-(С3-C8 гетероциклила), -(С3-C8 гетероциклил)-(СН2)r, (CH2)rC(O)NRb(CH2)r-, -(СН2СН2О)r-, -(CH2CH2O)rCH2-, (CH2)rC(O)NRb(CH2CH2O)r-, -(CH2)rC(O)NRb(CH2CH2O)rCH2-, (CH2CH2O)rC(O)NRb(CH2CH2O)r-, -(CH2CH2O)rC(O)NRb(CH2CH2O)rCH2- и -(CH2CH2O)rC(O)NRb(CH2)r-; где Rb означает Н, C1-С6 алкил, фенил или бензил; и r независимо означает целое число, находящееся в интервале от 1 до 10.
43. Иммуноконъюгат по п.41, где Ww является валин-цитруллином.
44. Иммуноконъюгат по п.42, где R17 является (СН2)5 или (СН2)2.
47. Фармацевтическая композиция для лечения и детектирования клеточно-пролиферативных нарушений, ассоциированных с увеличенной экспрессией STEAP-1, содержащая эффективное количество иммуноконъюгата по п.38 и фармацевтически приемлемый разбавитель, носитель или эксципиент.
48. Способ лечения рака, ассоциированного с увеличенной экспрессией STEAP-1, предусматривающий введение пациенту фармацевтической композиции по п.47.
49. Способ по п.48, где рак выбран из группы, состоящей из рака предстательной железы, рака легкого, рака ободочной кишки, рака мочевого пузыря, рака яичника и саркомы Юинга.
50. Способ по п.48, где пациенту вводят химиотерапевтический агент в комбинации с иммуноконъюгатом, где химиотерапевтический агент выбран из летрозола, цисплатина, карбоплатина, таксола, паклитаксела, оксалиплатина, доксетаксела, 5-ФУ, лейковорина, лапатиниба и гемцитабина.
51. Антитело по п.32, содержащее цистеин в одном или нескольких положениях, выбранных из 15, 43, 110, 144, 168 и 205 легкой цепи, в соответствии с нумерацией Кабата, и 41, 88, 115, 118, 120, 171, 172, 282, 375 и 400 тяжелой цепи, в соответствии с нумерацией EU.
52. Антитело по п.51, где цистеин находится в положении 205 легкой цепи.
53. Антитело по п.51, где цистеин находится в положении 118 тяжелой цепи.
56. Антитело по п.1, где LC содержит
(1) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:90;
(2) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:92;
(3) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:93;
(4) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:94;
(5) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:95;
(6) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:96;
(7) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:97;
(8) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:98;
(9) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:99;
(10) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:100; или
(11) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:101.
(1) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:90;
(2) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:92;
(3) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:93;
(4) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:94;
(5) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:95;
(6) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:96;
(7) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:97;
(8) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:98;
(9) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:99;
(10) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:100; или
(11) район легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:101.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86329506P | 2006-10-27 | 2006-10-27 | |
US60/863,295 | 2006-10-27 | ||
US86870706P | 2006-12-05 | 2006-12-05 | |
US60/868,707 | 2006-12-05 | ||
US92130007P | 2007-03-30 | 2007-03-30 | |
US60/921,300 | 2007-03-30 | ||
US93785707P | 2007-06-29 | 2007-06-29 | |
US60/937,857 | 2007-06-29 | ||
PCT/US2007/082726 WO2008052187A2 (en) | 2006-10-27 | 2007-10-26 | Antibodies and immunoconjugates and uses therefor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013115284A Division RU2639543C9 (ru) | 2006-10-27 | 2007-10-26 | Антитела и иммуноконъюгаты и их применения |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009119976A RU2009119976A (ru) | 2010-12-10 |
RU2483080C2 true RU2483080C2 (ru) | 2013-05-27 |
Family
ID=39165835
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013115284A RU2639543C9 (ru) | 2006-10-27 | 2007-10-26 | Антитела и иммуноконъюгаты и их применения |
RU2009119976/10A RU2483080C2 (ru) | 2006-10-27 | 2007-10-26 | Антитела и иммуноконъюгаты и их применение |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013115284A RU2639543C9 (ru) | 2006-10-27 | 2007-10-26 | Антитела и иммуноконъюгаты и их применения |
Country Status (30)
Country | Link |
---|---|
US (5) | US8436147B2 (ru) |
EP (3) | EP2845866B1 (ru) |
KR (2) | KR101541550B1 (ru) |
AR (1) | AR063532A1 (ru) |
AU (1) | AU2007308792B2 (ru) |
BR (1) | BRPI0717638A2 (ru) |
CA (1) | CA2667019C (ru) |
CO (1) | CO6180431A2 (ru) |
CR (1) | CR10734A (ru) |
CY (3) | CY1113074T1 (ru) |
DK (3) | DK2061814T3 (ru) |
ES (3) | ES2636089T3 (ru) |
HK (3) | HK1131626A1 (ru) |
HR (2) | HRP20120683T1 (ru) |
HU (1) | HUE034263T2 (ru) |
IL (1) | IL197928A (ru) |
LT (1) | LT2845866T (ru) |
MA (1) | MA30910B1 (ru) |
MX (1) | MX2009003938A (ru) |
NO (1) | NO20092052L (ru) |
NZ (1) | NZ576132A (ru) |
PE (2) | PE20081266A1 (ru) |
PL (3) | PL2061814T3 (ru) |
PT (3) | PT2502938E (ru) |
RS (2) | RS53942B1 (ru) |
RU (2) | RU2639543C9 (ru) |
SI (2) | SI2845866T1 (ru) |
TW (1) | TWI428347B (ru) |
WO (1) | WO2008052187A2 (ru) |
ZA (1) | ZA201002209B (ru) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11078284B2 (en) | 2014-10-01 | 2021-08-03 | Medimmune Limited | Antibodies specific for LOX1 and use in treatment of cardiovascular disorders |
RU2754684C2 (ru) * | 2014-09-30 | 2021-09-06 | Дойчес Кребсфоршунгсцентрум Штифтунг Дес Эффентлихен Рехтс | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) |
RU2784586C2 (ru) * | 2017-07-20 | 2022-11-28 | ЭнБиИ - ТЕРАПЬЮТИКС АГ | Человеческие антитела, связывающиеся с ror2 |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
MX2009003938A (es) | 2006-10-27 | 2009-04-24 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
AU2009246516B2 (en) * | 2008-05-13 | 2015-03-05 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
EP2358393A1 (en) * | 2008-11-20 | 2011-08-24 | F.Hoffmann-La Roche Ag | Therapeutic protein formulations |
WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
WO2011000054A1 (en) | 2009-07-03 | 2011-01-06 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
EP2516462B1 (en) * | 2009-12-23 | 2015-05-06 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
ES2581314T3 (es) * | 2010-03-02 | 2016-09-05 | Seattle Genetics, Inc. | Métodos de cribado de anticuerpos |
CN103119442A (zh) * | 2010-06-03 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 抗体和免疫偶联物的免疫peg成像及其用途 |
CA2801971C (en) | 2010-06-10 | 2018-07-24 | Hans-Georg Lerchen | Novel auristatin derivatives and their use |
RS56599B1 (sr) * | 2010-06-15 | 2018-02-28 | Genmab As | Konjugati humanog antitela sa lekom protiv tkivnog faktora |
CN103379912B (zh) * | 2010-09-29 | 2016-03-16 | 西雅图基因公司 | 正羧烷基耳他汀及其应用 |
KR102295534B1 (ko) | 2010-09-29 | 2021-08-30 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc) |
CN101942026B (zh) * | 2010-10-14 | 2014-08-27 | 成都正能生物技术有限责任公司 | 长效干扰素融合蛋白及其用途 |
PE20140238A1 (es) | 2010-11-10 | 2014-03-07 | Genentech Inc | Metodos y composiciones para inmunoterapia para enfermedad neural |
MX346784B (es) | 2010-11-12 | 2017-03-31 | Inovio Pharmaceuticals Inc | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. |
RU2440142C1 (ru) * | 2011-02-07 | 2012-01-20 | Общество С Ограниченной Ответственностью "Онкомакс" | Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований |
WO2012123423A1 (de) | 2011-03-16 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | N-carboxyalkyl-auristatine und ihre verwendung |
WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2013033359A1 (en) * | 2011-08-31 | 2013-03-07 | The Trustees Of The University Of Pennsylvania | Carbon nanotube biosensors and related methods |
US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
AU2015264844B2 (en) * | 2011-11-17 | 2016-09-01 | Pfizer Inc. | Cytotoxic peptides and antibody drug conjugates thereof |
PE20190515A1 (es) * | 2011-11-17 | 2019-04-10 | Pfizer | Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos |
SG11201402711SA (en) | 2011-11-29 | 2014-06-27 | Genentech Inc | Compositions and methods for prostate cancer analysis |
CN104302408B (zh) | 2012-02-27 | 2016-12-14 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
KR20150003251A (ko) | 2012-04-04 | 2015-01-08 | 가부시키가이샤 페르세우스 프로테오믹스 | 항 cdh3(p-카드헤린) 항체의 약물 콘쥬게이트 |
CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
TR201900694T4 (tr) * | 2012-08-23 | 2019-02-21 | Agensys Inc | 158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc). |
SG11201503469WA (en) | 2012-11-07 | 2015-06-29 | Pfizer | Anti-notch3 antibodies and antibody-drug conjugates |
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
EP3929217A3 (en) | 2013-02-08 | 2022-03-02 | Novartis AG | Specific sites for modifying antibodies to make immunoconjugates |
EA201891502A1 (ru) | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
AU2014233385C1 (en) * | 2013-03-15 | 2019-09-19 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
WO2014165818A2 (en) | 2013-04-05 | 2014-10-09 | T Cell Therapeutics, Inc. | Compositions and methods for preventing and treating prostate cancer |
EP3038624A1 (en) | 2013-08-26 | 2016-07-06 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
EP3049111A2 (en) | 2013-09-25 | 2016-08-03 | Cytomx Therapeutics Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
MX367851B (es) | 2013-10-11 | 2019-09-09 | Mersana Therapeutics Inc | Conjugados de proteína-polímero-fármaco. |
WO2015054669A1 (en) | 2013-10-11 | 2015-04-16 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
CN114671954A (zh) | 2014-01-10 | 2022-06-28 | 博笛生物科技有限公司 | 靶向her2阳性肿瘤的化合物和组合物 |
CN106413756A (zh) * | 2014-01-24 | 2017-02-15 | 豪夫迈·罗氏有限公司 | 使用抗steap1抗体和免疫缀合物的方法 |
EP4176896A1 (en) | 2014-01-31 | 2023-05-10 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于***的抗-pd-l1结合物 |
CN107074958A (zh) | 2014-07-09 | 2017-08-18 | 博笛生物科技有限公司 | 用于***的抗‑pd‑l1组合 |
US11415546B2 (en) | 2014-09-05 | 2022-08-16 | The Trustees Of The University Of Pennsylvania | Volatile organic compound-based diagnostic systems and methods |
CN107250158B (zh) | 2014-11-19 | 2022-03-25 | 基因泰克公司 | 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法 |
EP3221364B1 (en) | 2014-11-19 | 2020-12-16 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
SG11201706292SA (en) | 2015-02-16 | 2017-09-28 | Lonza Ag | Cl and/or ch1 mutated antibodies for drug conjugation |
US10017577B2 (en) | 2015-06-15 | 2018-07-10 | Genentech, Inc. | Antibodies and immunoconjugates |
US20170096495A1 (en) * | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
BR112018000835A2 (pt) * | 2015-10-02 | 2018-09-11 | Hoffmann La Roche | molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
CN115554406A (zh) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于***的抗-cd20组合 |
CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于***的抗-egfr组合 |
CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于***的抗-her2组合 |
CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
MY198605A (en) | 2016-01-25 | 2023-09-08 | Regeneron Pharma | Maytansinoid derivatives conjugates thereof, and methods of use |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
MA46952A (fr) | 2016-12-01 | 2019-10-09 | Regeneron Pharma | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet |
CN108271193B (zh) * | 2016-12-30 | 2020-07-10 | ***通信集团公司 | 一种业务容灾探测方法、mme及sgw |
MX2019010028A (es) | 2017-02-28 | 2019-10-14 | Seattle Genetics Inc | Anticuerpos con cisteina mutada por conjugacion. |
KR102667951B1 (ko) * | 2017-04-03 | 2024-05-22 | 에프. 호프만-라 로슈 아게 | Steap-1에 결합하는 항체 |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
CA3098491A1 (en) * | 2017-06-20 | 2018-12-27 | Sichuan Baili Pharm Co. Ltd | Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc) |
EP3641771A4 (en) | 2017-06-23 | 2020-12-16 | Birdie Biopharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
US20210299269A1 (en) | 2018-06-01 | 2021-09-30 | Eisai R&D Management Co., Ltd. | Splicing modulator antibody-drug conjugates and methods of use |
TW202016081A (zh) | 2018-06-21 | 2020-05-01 | 英商克拉德夫製藥有限公司 | 人類sting之小分子調節劑、結合物及治療應用 |
MA53094A (fr) * | 2018-07-02 | 2021-05-12 | Amgen Inc | Protéine de liaison à l'antigène anti-steap1 |
SG11202100464UA (en) * | 2018-07-18 | 2021-02-25 | Amgen Inc | Chimeric receptors to steap1 and methods of use thereof |
WO2020041532A1 (en) * | 2018-08-21 | 2020-02-27 | Sf17 Therapeutics, Inc. | Compositions and methods for treating progressive neurodegenerative diseases |
CN110872324B (zh) * | 2018-08-29 | 2021-09-14 | 中国科学院上海药物研究所 | 奥沙利铂偶联前药、其制备方法及用途 |
CA3116314A1 (en) * | 2018-10-15 | 2020-04-23 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against human dickkopf3 and uses thereof |
CN113271981A (zh) | 2018-12-13 | 2021-08-17 | 卫材R&D管理有限公司 | 荷伯希二烯抗体-药物缀合物及使用方法 |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
US20220298115A1 (en) | 2019-07-25 | 2022-09-22 | Curadev Pharma Pvt. Ltd. | Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2) |
CN114929743A (zh) * | 2019-09-05 | 2022-08-19 | 纪念斯隆凯特琳癌症中心 | 抗steap1抗体及其用途 |
CN111073892B (zh) * | 2019-10-30 | 2023-11-17 | 广西科学院 | 一种识别石斑鱼虹彩病毒感染细胞的核酸适配体及其构建方法和应用 |
CA3197158A1 (en) * | 2020-09-28 | 2022-03-31 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
WO2023086833A1 (en) | 2021-11-09 | 2023-05-19 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
WO2023154890A2 (en) * | 2022-02-11 | 2023-08-17 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding steap1 |
WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
GB202208119D0 (en) | 2022-06-01 | 2022-07-13 | Univ Oslo Hf | Anti-steap1 car |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA005601B1 (ru) * | 1999-10-06 | 2005-04-28 | Байоджен, Инк. | Способ лечения злокачественных опухолей у млекопитающего, характеризующихся аномально высокой экспрессией лиганда, индуцирующего пролиферацию клеток (april) |
WO2005113601A2 (en) * | 2004-04-22 | 2005-12-01 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to steap-1 proteins |
WO2006034488A2 (en) * | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
Family Cites Families (222)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CH605550A5 (ru) * | 1972-06-08 | 1978-09-29 | Research Corp | |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
WO1985003357A1 (en) | 1984-01-30 | 1985-08-01 | Icrf Patents Ltd. | Improvements relating to growth factors |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5316757A (en) | 1984-10-18 | 1994-05-31 | Board Of Regents, The University Of Texas System | Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups |
US5342606A (en) | 1984-10-18 | 1994-08-30 | Board Of Regents, The University Of Texas System | Polyazamacrocyclic compounds for complexation of metal ions |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
JP3208427B2 (ja) | 1989-09-29 | 2001-09-10 | オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド | ヒトの生物学的流体中のneu関連タンパク質の検出及び定量 |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
ATE204902T1 (de) | 1990-06-29 | 2001-09-15 | Large Scale Biology Corp | Melaninproduktion durch transformierte mikroorganismen |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5480990A (en) | 1991-12-10 | 1996-01-02 | The Dow Chemical Company | Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents |
US5739294A (en) | 1991-12-10 | 1998-04-14 | The Dow Chemical Company | Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents |
US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
US5489525A (en) | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
JP3095175B2 (ja) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5385893A (en) | 1993-05-06 | 1995-01-31 | The Dow Chemical Company | Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
US5462725A (en) | 1993-05-06 | 1995-10-31 | The Dow Chemical Company | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
JP3469580B2 (ja) | 1993-10-01 | 2003-11-25 | 帝国臓器製薬株式会社 | 新規なペプチド誘導体 |
AU8116494A (en) | 1993-11-12 | 1995-06-13 | Kenichi Matsubara | Gene signature |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US5834456A (en) | 1996-02-23 | 1998-11-10 | The Dow Chemical Company | Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents |
WO1997038123A1 (en) | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
US5859045A (en) * | 1996-05-08 | 1999-01-12 | Novo Nordisk A/S Novo Alle | Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5824504A (en) | 1996-09-26 | 1998-10-20 | Elshourbagy; Nabil A. | Human 7-transmembrane receptor and DNA |
WO1998018489A1 (en) | 1996-10-30 | 1998-05-07 | The Uab Research Foundation | Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies |
DK0942968T3 (da) | 1996-12-03 | 2008-06-23 | Amgen Fremont Inc | Fuldt humane antistoffer, der binder EGFR |
US6800746B2 (en) * | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
ES2248891T3 (es) | 1997-02-25 | 2006-03-16 | Corixa Corporation | Compuestos para inmunodiagnostico de cancer de prostata y metodos para su uso. |
WO1998037093A2 (en) | 1997-02-25 | 1998-08-27 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO2003004622A2 (en) | 2001-03-21 | 2003-01-16 | Human Genome Sciences, Inc. | Human secreted proteins |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
WO1998053071A1 (en) | 1997-05-23 | 1998-11-26 | Biogen, Inc. | Modulators of tissue regeneration |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
DE69835751T2 (de) | 1997-08-01 | 2007-10-04 | Serono Genetics Institute S.A. | 5' ests für proteine, die nicht gewebespezifisch sind |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
JPH11164691A (ja) | 1997-10-03 | 1999-06-22 | Rikagaku Kenkyusho | 胚盤胞cDNA |
US20030060612A1 (en) * | 1997-10-28 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
JP2001521909A (ja) | 1997-10-31 | 2001-11-13 | ジェネンテク・インコーポレイテッド | 糖タンパク質グリコフォームを含む方法及び組成物 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
US6048970A (en) * | 1998-05-22 | 2000-04-11 | Incyte Pharmaceuticals, Inc. | Prostate growth-associated membrane proteins |
US20030064397A1 (en) * | 1998-05-22 | 2003-04-03 | Incyte Genomics, Inc. | Transmembrane protein differentially expressed in prostate and lung tumors |
US20030149531A1 (en) * | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US6833438B1 (en) * | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
IL139699A0 (en) * | 1998-06-01 | 2002-02-10 | Urogenesys Inc | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
TW200532020A (en) | 1998-07-14 | 2005-10-01 | Corixa Corp | Compositions and methods for therapy and diagnosis of prostate cancer |
CA2362423A1 (en) | 1998-12-17 | 2000-06-22 | Human Genome Sciences, Inc. | 47 human secreted proteins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
DK2270149T3 (en) | 1999-04-09 | 2016-05-09 | Kyowa Hakko Kirin Co Ltd | PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE. |
NZ514918A (en) * | 1999-04-28 | 2003-11-28 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
AU5457000A (en) | 1999-06-11 | 2001-01-02 | Human Genome Sciences, Inc. | 48 human secreted proteins |
KR100850389B1 (ko) | 1999-06-25 | 2008-08-04 | 제넨테크, 인크. | 인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법 |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
AU6906800A (en) | 1999-08-17 | 2001-03-13 | Incyte Genomics, Inc. | Membrane associated proteins |
GB2354821A (en) | 1999-09-29 | 2001-04-04 | Dine O Quick | Threshold crossing counter |
WO2001025272A2 (en) | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
US6372907B1 (en) | 1999-11-03 | 2002-04-16 | Apptera Corporation | Water-soluble rhodamine dye peptide conjugates |
EP1230364A2 (en) | 1999-11-12 | 2002-08-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
IL150018A0 (en) | 1999-12-06 | 2002-12-01 | Agensys Inc | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
PT1240337E (pt) | 1999-12-24 | 2007-01-31 | Genentech Inc | Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos |
MXPA02006934A (es) | 2000-01-14 | 2003-01-28 | Corixa Corp | Composiciones y metodos para la terapia y diagnostico de cancer de prostata. |
EP1572987A4 (en) | 2000-02-03 | 2005-11-30 | Nuvelo Inc | NUCLEIC ACIDS AND POLYPEPTIDES |
AU2001236589A1 (en) | 2000-02-04 | 2001-08-14 | Aeomica, Inc. | Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes |
AU2001241541A1 (en) | 2000-02-17 | 2001-08-27 | Millennium Predictive Medicine, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
CA2403637A1 (en) | 2000-03-24 | 2001-10-04 | Fahri Saatcioglu | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
AU2001249549A1 (en) | 2000-03-27 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
JP2004509612A (ja) | 2000-06-05 | 2004-04-02 | アバロン ファーマシューティカルズ | ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング |
CA2412223A1 (en) | 2000-06-09 | 2001-12-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
AU2002210791A1 (en) | 2000-07-28 | 2002-02-13 | Compugen Inc. | Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome |
EP1445318A2 (en) | 2000-08-24 | 2004-08-11 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
AU2002215345A1 (en) | 2000-10-13 | 2002-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer |
WO2002059260A2 (en) | 2000-11-17 | 2002-08-01 | Hyseq, Inc. | Nucleic acids and polypeptides |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
US20030055220A1 (en) | 2001-01-12 | 2003-03-20 | Pierre Legrain | Protein-protein interactions between Shigella flexneri polypeptides and mammalian polypeptides |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US20030108963A1 (en) | 2001-07-25 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer |
NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US7494646B2 (en) * | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
CA2459318C (en) | 2001-09-06 | 2017-09-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
EP1308459A3 (en) | 2001-11-05 | 2003-07-09 | Research Association for Biotechnology | Full-length cDNA sequences |
JP2005511627A (ja) | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス,インコーポレーテッド | 抗cd30抗体を使用する免疫学的疾患の治療 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
WO2003084570A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia |
AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
WO2003085102A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
AU2002312598B2 (en) | 2002-06-20 | 2008-08-28 | Snaptrack Incorporated | Reducing cross-interference in a combined GPS receiver and communication system |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
DK2357006T3 (en) | 2002-07-31 | 2015-12-21 | Seattle Genetics Inc | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP1575514A2 (en) | 2002-07-31 | 2005-09-21 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CA2499300A1 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
KR20070055625A (ko) | 2002-12-16 | 2007-05-30 | 제넨테크, 인크. | 이뮤노글로불린 변이체 및 이들의 용도 |
CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
LT2348051T (lt) | 2003-11-05 | 2019-02-25 | Roche Glycart Ag | Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija |
CN1938046B (zh) * | 2003-11-06 | 2014-03-19 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
EP1769092A4 (en) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | IMPROVED LIXIVIATION OF BASE METALS |
DK3248613T3 (da) | 2005-07-18 | 2022-03-14 | Seagen Inc | Beta-glucuronid-lægemiddel-linkerkonjugater |
MX2009003938A (es) | 2006-10-27 | 2009-04-24 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
EP2358393A1 (en) | 2008-11-20 | 2011-08-24 | F.Hoffmann-La Roche Ag | Therapeutic protein formulations |
-
2007
- 2007-10-26 MX MX2009003938A patent/MX2009003938A/es active IP Right Grant
- 2007-10-26 SI SI200731940A patent/SI2845866T1/sl unknown
- 2007-10-26 RU RU2013115284A patent/RU2639543C9/ru not_active IP Right Cessation
- 2007-10-26 DK DK07863572.9T patent/DK2061814T3/da active
- 2007-10-26 PL PL07863572T patent/PL2061814T3/pl unknown
- 2007-10-26 CA CA2667019A patent/CA2667019C/en not_active Expired - Fee Related
- 2007-10-26 LT LTEP14171013.7T patent/LT2845866T/lt unknown
- 2007-10-26 DK DK14171013.7T patent/DK2845866T3/en active
- 2007-10-26 RS RS20150256A patent/RS53942B1/en unknown
- 2007-10-26 PL PL14171013T patent/PL2845866T3/pl unknown
- 2007-10-26 EP EP14171013.7A patent/EP2845866B1/en active Active
- 2007-10-26 ES ES14171013.7T patent/ES2636089T3/es active Active
- 2007-10-26 WO PCT/US2007/082726 patent/WO2008052187A2/en active Application Filing
- 2007-10-26 KR KR1020097010761A patent/KR101541550B1/ko active IP Right Grant
- 2007-10-26 DK DK12167198T patent/DK2502938T3/en active
- 2007-10-26 ES ES07863572T patent/ES2387924T3/es active Active
- 2007-10-26 SI SI200731642T patent/SI2502938T1/sl unknown
- 2007-10-26 PT PT121671986T patent/PT2502938E/pt unknown
- 2007-10-26 HU HUE14171013A patent/HUE034263T2/en unknown
- 2007-10-26 PT PT07863572T patent/PT2061814E/pt unknown
- 2007-10-26 RU RU2009119976/10A patent/RU2483080C2/ru not_active IP Right Cessation
- 2007-10-26 ES ES12167198.6T patent/ES2535637T3/es active Active
- 2007-10-26 BR BRPI0717638-4A2A patent/BRPI0717638A2/pt not_active Application Discontinuation
- 2007-10-26 KR KR1020147023731A patent/KR20140116546A/ko not_active Application Discontinuation
- 2007-10-26 NZ NZ576132A patent/NZ576132A/en not_active IP Right Cessation
- 2007-10-26 US US11/978,122 patent/US8436147B2/en active Active
- 2007-10-26 RS RS20120371A patent/RS52452B/en unknown
- 2007-10-26 AU AU2007308792A patent/AU2007308792B2/en not_active Ceased
- 2007-10-26 EP EP07863572A patent/EP2061814B1/en active Active
- 2007-10-26 EP EP12167198.6A patent/EP2502938B1/en active Active
- 2007-10-26 PT PT141710137T patent/PT2845866T/pt unknown
- 2007-10-26 PL PL12167198T patent/PL2502938T3/pl unknown
- 2007-10-29 PE PE2007001473A patent/PE20081266A1/es not_active Application Discontinuation
- 2007-10-29 TW TW096140634A patent/TWI428347B/zh not_active IP Right Cessation
- 2007-10-29 PE PE2012000391A patent/PE20121023A1/es active IP Right Grant
- 2007-10-29 AR ARP070104790A patent/AR063532A1/es not_active Application Discontinuation
-
2009
- 2009-04-03 CO CO09034904A patent/CO6180431A2/es active IP Right Grant
- 2009-04-05 IL IL197928A patent/IL197928A/en active IP Right Grant
- 2009-04-20 CR CR10734A patent/CR10734A/es unknown
- 2009-05-21 MA MA31905A patent/MA30910B1/fr unknown
- 2009-05-26 NO NO20092052A patent/NO20092052L/no not_active Application Discontinuation
- 2009-11-06 HK HK09110356.8A patent/HK1131626A1/xx unknown
- 2009-11-06 HK HK13100563.2A patent/HK1173161A1/xx unknown
-
2010
- 2010-03-29 ZA ZA2010/02209A patent/ZA201002209B/en unknown
-
2012
- 2012-08-24 CY CY20121100768T patent/CY1113074T1/el unknown
- 2012-08-27 HR HRP20120683TT patent/HRP20120683T1/hr unknown
-
2013
- 2013-02-13 US US13/766,150 patent/US8889847B2/en active Active
-
2014
- 2014-10-17 US US14/517,682 patent/US9593167B2/en active Active
-
2015
- 2015-05-12 CY CY20151100417T patent/CY1116261T1/el unknown
- 2015-05-13 HR HRP20150508TT patent/HRP20150508T1/hr unknown
- 2015-09-08 HK HK15108753.3A patent/HK1208228A1/xx unknown
-
2017
- 2017-01-25 US US15/415,379 patent/US20170234883A1/en not_active Abandoned
- 2017-07-20 CY CY20171100779T patent/CY1119102T1/el unknown
- 2017-12-21 US US15/849,962 patent/US20180106809A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA005601B1 (ru) * | 1999-10-06 | 2005-04-28 | Байоджен, Инк. | Способ лечения злокачественных опухолей у млекопитающего, характеризующихся аномально высокой экспрессией лиганда, индуцирующего пролиферацию клеток (april) |
WO2005113601A2 (en) * | 2004-04-22 | 2005-12-01 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to steap-1 proteins |
WO2006034488A2 (en) * | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
Non-Patent Citations (1)
Title |
---|
РОЙТ и др. «Иммунология», пер. с англ. - М.: Мир, 2000, с.110, 150. * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2754684C2 (ru) * | 2014-09-30 | 2021-09-06 | Дойчес Кребсфоршунгсцентрум Штифтунг Дес Эффентлихен Рехтс | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) |
US11078284B2 (en) | 2014-10-01 | 2021-08-03 | Medimmune Limited | Antibodies specific for LOX1 and use in treatment of cardiovascular disorders |
RU2764993C2 (ru) * | 2014-10-01 | 2022-01-24 | Медиммьюн Лимитед | Связывающие белки, специфичные в отношении lox1, и пути их применения |
RU2817838C2 (ru) * | 2015-09-25 | 2024-04-22 | Дженентек, Инк. | Анти-tigit антитела и способы применения |
RU2784586C2 (ru) * | 2017-07-20 | 2022-11-28 | ЭнБиИ - ТЕРАПЬЮТИКС АГ | Человеческие антитела, связывающиеся с ror2 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2483080C2 (ru) | Антитела и иммуноконъюгаты и их применение | |
JP2010523469A5 (ru) | ||
RU2423382C1 (ru) | Композиции и способы диагностики и лечения опухоли | |
JP2016063817A5 (ru) | ||
RU2008141171A (ru) | Анти-тат226 антитела и иммуноконъюгаты | |
JP2013056896A5 (ru) | ||
RU2021125492A (ru) | Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения | |
JP6333882B2 (ja) | 抗体−薬剤コンジュゲート | |
RU2011144119A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
RU2011144141A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
JP2014139173A5 (ru) | ||
JP2012522513A5 (ru) | ||
JP2019146572A5 (ru) | ||
JP2017110002A5 (ru) | ||
JP2015523961A5 (ru) | ||
JP2015528818A5 (ru) | ||
JP2017534253A5 (ru) | ||
JP2011514146A5 (ru) | ||
JP2015523380A5 (ru) | ||
JP2016523810A5 (ru) | ||
RU2014148162A (ru) | Анти-pmel17 антитела и их иммуноконъюгаты | |
JP2019535731A5 (ru) | ||
JP2016512832A5 (ru) | ||
RU2011140491A (ru) | Конъюгаты антитело-лекарственное средство, которые связывают белки 24р4с12 | |
JP2015527318A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20191027 |